Tech-heavy indices are sliding after concerns about stricter rules on AI data centres and chipmakers, yet many Australian businesses built and still run by their original founders are not priced on AI hype at all. These leaders often think in decades, not quarters, and keep meaningful skin in the game. This article highlights three founder-led Australian stocks from our screener that show how that long-term mindset can reshape both risk and reward. The three stocks highlighted here offer a...
Australian shares closed higher on Thursday, tracking Wall Street gains after the US Federal Reserve
Mesoblast Ltd (ASX:MSB, NASDAQ:MESO) shares surged nearly 24% to $2.33 in afternoon trading after the cell therapy developer reported strong first-quarter revenue growth and a sharp reduction in operating cash spend. The US-focused biotechnology group reported Ryoncil net revenue of US$28...
Detailed price information for Mesoblast Ltd (MEOBF) from The Globe and Mail including charting and trades.
Mesoblast's Ryoncil provides commercial validation for its cell-therapy platform while helping finance additional development. Learn more about MESO stock here.
Detailed price information for Mesoblast Ltd ADR (MESO-Q) from The Globe and Mail including charting and trades.
Find out all the key statistics for Mesoblast Ltd (MEOBF), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.
Detailed price information for Mesoblast Ltd (MEOBF) from The Globe and Mail including charting and trades.
Mesoblast (MESO) said Thursday that the US Food and Drug Administration approved a new potency assay
Tipranks Press Release.
Detailed price information for Mesoblast Ltd (MEOBF) from The Globe and Mail including charting and trades.
RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment
Mesoblast (NASDAQ:MESO) reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company’s FDA-approved allogeneic mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, or GVHD. Chief Executive Of
RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026). Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very p
Tipranks Press Release.
NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the...
This is the newest page. Registered accounts read further back.